Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?
How do retina specialists decide which wet AMD patients are best suited for extended duration therapy and which patients should continue with more traditional intervention? In the second episode of this season of \u201cThe Art of Drug Choice,\u201d moderator Arshad M. Khanani, MD, MA, asks Lejla Vajzovic, MD, and Joseph M. Coney, MD, about which factors they weigh most heavily when determining if a patient could be a good candidate for a change in treatment strategy, and discuss how gene therapy may play a role in wet AMD treatment. After the break, Dr. Vajzovic reviews the case of a patient who has undergone treatment with three different anti-VEGF agents. Why and when did she switch this patient to a different therapy?\n\nThis editorially independent podcast is supported with advertising.